Development and Physicochemical Characterization of An Empagliflozin-Loaded Oral Nanoemulsion: Formulation Optimization, in Vitro Release Kinetics, and Exploratory Ex Vivo Intestinal Permeation
Background: Empagliflozin is a selective sodium–glucose cotransporter-2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. Its intestinal permeability presents an opportunity for improving oral drug delivery through lipid-based nanocarriers. The present study aimed to develop, screen, and characteriz...